Xavier Calvo

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 59 publications

Incorporation of Genomic Determinants Improves Diagnostic Accuracy of Oligomonocytic Chronic Myelomonocytic Leukemia.

Incorporation of Genomic Determinants Improves Diagnostic Accuracy of Oligomonocytic Chronic Myelomonocytic Leukemia.

Journal: Blood cancer discovery
Published: July 17, 2025

Unveiling relative lymphopenia and elevated monocyte-to-lymphocyte count as novel independent adverse prognostic factors in chronic myelomonocytic leukemia (CMML)-Proposal of the objective prognostic index for CMML (OPIC).

Unveiling relative lymphopenia and elevated monocyte-to-lymphocyte count as novel independent adverse prognostic factors in chronic myelomonocytic leukemia (CMML)-Proposal of the objective prognostic index for CMML (OPIC).

Journal: HemaSphere
Published: May 06, 2025

Genomic characterization of clonal B-cell lymphocytosis of marginal zone origin with MYC rearrangements.

Genomic characterization of clonal B-cell lymphocytosis of marginal zone origin with MYC rearrangements.

Journal: Virchows Archiv : an international journal of pathology
Published: April 30, 2025

Primary Cutaneous Peripheral T-Cell Lymphoma With Follicular Helper T-Cell Phenotype.

Primary Cutaneous Peripheral T-Cell Lymphoma With Follicular Helper T-Cell Phenotype.

Journal: Journal of cutaneous pathology
Published: February 25, 2025

Combined immunohistochemical profile CD10/LMO2/MYC is a useful tool to screen MYC rearrangements in aggressive large B-cell lymphomas.

Combined immunohistochemical profile CD10/LMO2/MYC is a useful tool to screen MYC rearrangements in aggressive large B-cell lymphomas.

Journal: Virchows Archiv : an international journal of pathology
Published: August 16, 2024

The IL-1β inhibitor canakinumab in previously treated lower-risk myelodysplastic syndromes: a phase 2 clinical trial.

The IL-1β inhibitor canakinumab in previously treated lower-risk myelodysplastic syndromes: a phase 2 clinical trial.

Journal: Nature communications
Published: July 15, 2024

AML typical mutations (CEBPA, FLT3, NPM1) identify a high-risk chronic myelomonocytic leukemia independent of CPSS molecular.

AML typical mutations (CEBPA, FLT3, NPM1) identify a high-risk chronic myelomonocytic leukemia independent of CPSS molecular.

Journal: Blood advances
Published: May 14, 2024

Chromogenic LMO2 mRNA ISH Expression Correlates with LMO2 Protein and Gene Expression and Captures Their Survival Impact in Diffuse Large B-Cell Lymphoma, NOS.

Chromogenic LMO2 mRNA ISH Expression Correlates with LMO2 Protein and Gene Expression and Captures Their Survival Impact in Diffuse Large B-Cell Lymphoma, NOS.

Journal: Cancers
Published: May 11, 2024

Acute myeloid leukemia at first relapse: approaching the precipice.

Acute myeloid leukemia at first relapse: approaching the precipice.

Journal: Haematologica
Published: May 06, 2024

Complex Karyotype Detection in Chronic Lymphocytic Leukemia: A Comparison of Parallel Cytogenetic Cultures Using TPA and IL2+DSP30 from a Single Center.

Complex Karyotype Detection in Chronic Lymphocytic Leukemia: A Comparison of Parallel Cytogenetic Cultures Using TPA and IL2+DSP30 from a Single Center.

Journal: Cancers
Published: April 30, 2024

Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes.

Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes.

Journal: Nature communications
Published: August 25, 2023

Leukemic Involvement Is a Common Feature in Waldenström Macroglobulinemia at Diagnosis.

Leukemic Involvement Is a Common Feature in Waldenström Macroglobulinemia at Diagnosis.

Journal: Cancers
Published: July 21, 2023
Showing 1-12 of 59

Last Updated: 09/26/2026